Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …

Cancer treatment today employs a combination of chemotherapy, radiotherapy, and surgery
to prolong life and provide cure. However, many of these treatments can cause …

Abstract Mutations in the Bcr-Abl kinase domain may cause, or contribute to, resistance to
tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia patients. Recommendations …

Efforts to discover new cancer drugs and predict their clinical activity are limited by the fact
that laboratory models to test drug efficacy do not faithfully recapitulate this complex disease …

Abstract Bosutinib, a dual Src/Abl kinase inhibitor, has shown potent activity against chronic
myeloid leukemia (CML). In this phase 1/2 study we evaluated bosutinib in patients with …

Vascular safety is an emerging issue in patients with chronic myeloid leukemia (CML)
treated with tyrosine kinase inhibitors (TKIs). Whereas imatinib exhibits a well-documented …

Multidrug resistance is the most widely exploited phenomenon by which cancer eludes
chemotherapy. Broad variety of factors, ranging from the cellular ones, such as over …

Throughout its history, chronic myeloid leukemia (CML) has set precedents for cancer
research and therapy. These range from the identification of the first specific chromosomal …

Chronic Myeloid Leukemia (CML) is a clonal disease characterized by the presence of the
Philadelphia (Ph+) chromosome and its oncogenic product, BCR-ABL, a constitutively active …

Few neoplastic diseases have undergone a transformation in a relatively short period like
chronic myeloid leukemia (CML) has in the last few years. In 1960, CML was the first cancer …